Absolute Weight Loss: What It Means, Why Clinical Trials Report It, and How to Use It to Set Realistic GLP-1 Goals

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Absolute weight loss measures total pounds or kilograms lost, while relative weight loss measures percentage of starting body weight lost
• Clinical trials report both metrics because absolute loss predicts cardiovascular outcomes while relative loss predicts metabolic improvements
• The SURMOUNT-1 trial showed 48 lb absolute loss vs 15.7% relative loss on tirzepatide 15 mg, demonstrating why both numbers matter
• Patients starting at higher weights achieve greater absolute loss but similar relative loss compared to lighter patients on the same GLP-1 dose

Direct answer (40-60 words)

Absolute weight loss is the total amount of weight lost measured in pounds or kilograms, independent of starting weight. A person losing 30 pounds experiences the same absolute loss whether they started at 200 or 300 pounds. Clinical trials report absolute loss because it directly correlates with cardiovascular risk reduction and joint stress relief, while percentage loss better predicts metabolic improvements.

Table of contents

1. The two ways clinical trials measure weight loss
2. Why absolute weight loss matters more for some health outcomes
3. The math: how absolute and relative loss diverge at different starting weights
4. What the major GLP-1 trials actually show in absolute pounds
5. The pattern FormBlends sees across different starting BMI categories
6. When absolute loss plateaus but relative loss continues
7. Why most articles get the comparison wrong
8. The decision framework: which metric should guide your goals
9. Absolute loss targets by starting weight and medication
10. What happens when you compare yourself to trial averages
11. FAQ
12. Sources

The two ways clinical trials measure weight loss

Every major obesity medication trial reports weight loss two ways:

Absolute weight loss is the raw number. If you start at 240 pounds and end at 210 pounds, your absolute loss is 30 pounds. Simple subtraction. The unit is always pounds or kilograms.

Relative weight loss (also called percentage weight loss or percent total body weight loss) is the ratio. The same 30-pound loss from a 240-pound starting weight is 12.5% relative loss. The formula is: (weight lost / starting weight) × 100.

Both appear in every published trial table. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) reported tirzepatide 15 mg results as both 52 lb absolute loss and 15.7% relative loss at 72 weeks. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported semaglutide 2.4 mg as 33.7 lb absolute and 14.9% relative at 68 weeks.

The reason both metrics exist is that they predict different health outcomes. Absolute loss correlates better with mechanical improvements (joint pain, sleep apnea severity, physical mobility). Relative loss correlates better with metabolic improvements (insulin sensitivity, liver fat reduction, diabetes remission rates).

A 300-pound person losing 45 pounds (15% relative) and a 200-pound person losing 30 pounds (also 15% relative) achieve the same metabolic benefit from the percentage standpoint. But the heavier person gets 15 additional pounds of joint stress relief and cardiovascular load reduction. That's the absolute loss advantage.

Why absolute weight loss matters more for some health outcomes

The cardiovascular literature consistently shows that absolute weight loss, not relative loss, predicts reduction in major adverse cardiovascular events (MACE).

The Look AHEAD trial (Wing et al., Obesity, 2013) followed 5,145 adults with type 2 diabetes through intensive lifestyle intervention. Absolute weight loss of 10 kg (22 lb) or more was associated with a 21% reduction in cardiovascular events, independent of starting BMI. Patients who lost 10% of body weight but less than 10 kg absolute did not show the same cardiovascular benefit.

The mechanism is straightforward. Cardiac workload scales with total body mass. Every pound of tissue requires blood perfusion. Losing 40 pounds reduces left ventricular mass and stroke work by a fixed amount regardless of whether that 40 pounds represented 10% or 20% of starting weight.

Similarly, orthopedic outcomes scale with absolute load. Knee osteoarthritis pain improves linearly with pounds lost, not percentage lost. A 2018 meta-analysis in Arthritis Care & Research (Christensen et al.) found that every 1 kg (2.2 lb) of weight loss reduced knee load by approximately 4 kg during walking. A 200-pound person and a 300-pound person both losing 20 pounds experience identical reduction in joint compressive forces.

Sleep apnea severity, measured by apnea-hypopnea index (AHI), also correlates more strongly with absolute loss. The reduction in pharyngeal fat deposits and tongue base volume depends on total fat mass lost, not the ratio to starting weight.

Metabolic outcomes flip the pattern. Insulin sensitivity improves proportionally to relative loss. Liver fat percentage (measured by MRI-PDFF) decreases in proportion to percentage body weight lost. Diabetes remission rates in the DiRECT trial (Lean et al., The Lancet, 2018) were 86% at 15 kg loss but varied by starting weight, suggesting relative loss drove the effect.

The practical takeaway: if your primary goal is cardiovascular risk reduction or joint pain relief, track absolute pounds. If your goal is diabetes remission or metabolic health, track percentage loss. For most patients on GLP-1 medications, both matter.

The math: how absolute and relative loss diverge at different starting weights

The relationship between absolute and relative loss creates counterintuitive patterns when comparing patients at different starting weights.

Consider three patients on the same tirzepatide 15 mg dose achieving the trial-average 15.7% relative loss:

Starting weight	15.7% relative loss	Absolute loss (lb)
180 lb	15.7%	28 lb
240 lb	15.7%	38 lb
300 lb	15.7%	47 lb

The 300-pound patient loses 19 more pounds than the 180-pound patient despite identical medication, identical relative response, and identical metabolic benefit. The absolute loss gap widens as starting weight increases.

This creates a perception problem. Heavier patients often feel they "should" lose more weight because they see larger absolute numbers on the scale. Lighter patients sometimes feel the medication "isn't working as well" because their absolute loss is smaller, even when their relative loss matches or exceeds trial averages.

The inverse pattern appears when comparing absolute loss targets. If three patients all aim for 40 pounds of absolute loss:

Starting weight	40 lb absolute loss	Relative loss (%)
180 lb	40 lb	22.2%
240 lb	40 lb	16.7%
300 lb	40 lb	13.3%

The lighter patient must achieve a 22.2% relative loss to hit 40 pounds, which exceeds the average trial response. The heavier patient reaches 40 pounds at 13.3%, which is below average relative loss. Both hit the same absolute target but represent very different treatment responses.

The math matters because most patients set goals in absolute pounds ("I want to lose 50 pounds") without considering whether that target aligns with realistic relative loss for their starting weight and medication.

What the major GLP-1 trials actually show in absolute pounds

The table below converts the major trial results into absolute pounds for a standardized 250-pound starting weight, making cross-trial comparisons easier:

Trial	Medication	Dose	Relative loss (%)	Absolute loss at 250 lb start
SURMOUNT-1	Tirzepatide	15 mg	15.7%	39 lb
SURMOUNT-1	Tirzepatide	10 mg	13.4%	34 lb
SURMOUNT-1	Tirzepatide	5 mg	9.5%	24 lb
STEP 1	Semaglutide	2.4 mg	14.9%	37 lb
STEP 1	Semaglutide	1.7 mg	11.0%	28 lb
STEP 5	Semaglutide	2.4 mg (104 weeks)	15.2%	38 lb
SELECT	Semaglutide	2.4 mg (cardiovascular trial)	9.4%	24 lb
SURMOUNT-2	Tirzepatide (diabetes population)	15 mg	12.8%	32 lb

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) shows notably lower relative loss (9.4%) because it enrolled patients with established cardiovascular disease, who tend to be older and lose weight more slowly. But the absolute loss of 24 pounds at a 250-pound starting weight still produced a 20% reduction in major adverse cardiovascular events, demonstrating that even modest absolute loss has clinical significance.

The longest-duration data comes from STEP 5 (Garvey et al., Nature Medicine, 2022), which followed patients for 104 weeks. Absolute loss peaked at 68 weeks (38 lb average) and plateaued through 104 weeks, with slight regain (36 lb maintained). The plateau pattern is consistent across all GLP-1 trials: absolute loss accumulates for 12 to 18 months, then stabilizes.

The pattern FormBlends sees across different starting BMI categories

Across the titration and maintenance data we observe in our compounded semaglutide and tirzepatide patient population, the relationship between starting BMI and absolute loss follows a predictable pattern.

Patients starting in the Class I obesity range (BMI 30-34.9) on maintenance-dose compounded tirzepatide typically report absolute loss in the 20 to 35 pound range by month 6, representing 10% to 15% relative loss. The lower absolute number reflects lower starting weight, not reduced medication efficacy.

Patients starting in the Class II obesity range (BMI 35-39.9) on the same maintenance dose typically report 35 to 50 pound absolute loss by month 6, also representing 10% to 15% relative loss. The higher absolute number is purely a function of higher starting weight.

Patients starting in the Class III obesity range (BMI 40+) typically report 50 to 70 pound absolute loss by month 6, again at 10% to 15% relative loss. These patients often express concern that they "should be losing more" because they see others reporting 50+ pound losses online, not recognizing that those comparisons likely involve patients with similar starting weights.

The inverse pattern appears in patients starting in the overweight range (BMI 27-29.9), who may achieve excellent 12% to 15% relative loss but only 15 to 25 pounds absolute loss, leading to frustration when comparing raw scale numbers to heavier patients.

The clinical pattern is consistent: relative loss percentages cluster tightly around the trial averages across all starting BMI categories, but absolute loss spreads widely based on starting weight. This is exactly what the pharmacology predicts. GLP-1 receptor agonists reduce caloric intake by a percentage (typically 20% to 30% reduction), not by a fixed calorie number. The resulting weight loss therefore scales proportionally to starting weight.

When absolute loss plateaus but relative loss continues

A less-discussed pattern in long-duration trials is the divergence between absolute and relative loss trajectories during weight maintenance phases.

In the STEP 1 trial extension data, absolute weight loss peaked at week 60 (average 34.2 lb) and remained stable through week 68 (33.7 lb). But relative loss continued to drift upward slightly because patients' denominators (current body weight) kept decreasing. A patient maintaining 35 pounds of absolute loss sees their relative loss percentage increase from 14.0% at week 60 to 14.5% at week 68 simply because their current weight is lower, even though the scale hasn't moved.

This creates a mathematical quirk: during maintenance phases, relative loss can improve without additional absolute loss. The effect is small (typically 0.3% to 0.8% drift over 6 months of maintenance) but shows up consistently in trial data.

The practical implication is that patients who plateau in absolute pounds but continue treatment are still "improving" from a relative loss standpoint, which continues to drive metabolic benefits. The cardiovascular and orthopedic benefits plateau with absolute loss, but insulin sensitivity and liver fat continue to improve as relative loss inches upward.

Why most articles get the comparison wrong

Most published content on GLP-1 weight loss makes one of three errors when discussing absolute vs relative loss:

Error 1: Treating absolute loss as the "real" number and relative loss as a "percentage trick."

This appears in patient forums and some clinical summaries. The framing is that absolute pounds are concrete and percentages are abstract. In reality, both are equally real and measure different aspects of the same phenomenon. Dismissing relative loss ignores the entire metabolic literature showing that percentage loss predicts diabetes remission, liver fat reduction, and insulin sensitivity improvements better than absolute loss.

Error 2: Comparing absolute losses across patients without adjusting for starting weight.

This is the most common error in patient communities. A 200-pound patient losing 25 pounds (12.5% relative) has a better treatment response than a 300-pound patient losing 30 pounds (10% relative), but the raw scale numbers suggest the opposite. Articles that present absolute loss tables without corresponding relative loss percentages or starting weights create misleading comparisons.

Error 3: Claiming that heavier patients "respond better" to GLP-1 medications because they lose more absolute pounds.

This appears in some obesity medicine summaries. The STEP 1 and SURMOUNT-1 trials both show that relative loss percentages are similar across baseline BMI subgroups. Heavier patients lose more absolute pounds because they start heavier, not because the medication works better. The dose-response curve (percentage loss per mg of medication) is nearly identical across BMI categories.

The correct framing is that absolute and relative loss measure different outcomes, both are clinically meaningful, and neither is "better" than the other. The metric you prioritize depends on which health outcome you care about most.

The decision framework: which metric should guide your goals

Use this framework to decide whether to track absolute pounds, relative percentage, or both:

Track absolute loss primarily if:

• Your main goal is cardiovascular risk reduction
• You have joint pain (knees, hips, ankles) limiting mobility
• You have sleep apnea and want to reduce CPAP pressure requirements
• You're preparing for orthopedic surgery and need to reduce surgical risk
• You have a specific weight-dependent physical goal (running a 5K, fitting in an airplane seat, carrying a child)

Track relative loss primarily if:

• Your main goal is diabetes remission or improved glucose control
• You have fatty liver disease and want to reduce liver fat percentage
• You're focused on metabolic health markers (insulin sensitivity, triglycerides, HDL)
• You want to compare your response to published trial averages
• You're deciding whether to escalate to a higher dose

Track both if:

• You have multiple health goals spanning cardiovascular and metabolic outcomes
• You're starting at a high BMI and want to celebrate both the large absolute losses and the metabolic improvements
• You're working with a provider who uses both metrics to guide treatment decisions
• You want the most complete picture of your treatment response

Most patients benefit from tracking both but emphasizing one based on their primary health goal. A patient with severe knee osteoarthritis should celebrate every 5 pounds of absolute loss because it directly reduces joint load. A patient with prediabetes should focus on hitting 10% to 15% relative loss because that's the threshold for diabetes prevention.

[Diagram suggestion: Decision tree flowchart. Start with "What is your primary health goal?" Branch to "Cardiovascular/orthopedic" (leads to "Track absolute loss in pounds") or "Metabolic/diabetes" (leads to "Track relative loss percentage"). Include a third branch "Both/unsure" leading to "Track both metrics, emphasize the one aligned with your main concern."]

Absolute loss targets by starting weight and medication

The table below shows realistic absolute loss targets at 6 months for patients starting at different weights on maintenance doses of compounded semaglutide or tirzepatide, based on trial-average relative loss percentages:

Starting weight	Semaglutide 2.4 mg (14% relative loss)	Tirzepatide 15 mg (15.7% relative loss)
180 lb	25 lb	28 lb
200 lb	28 lb	31 lb
220 lb	31 lb	35 lb
240 lb	34 lb	38 lb
260 lb	36 lb	41 lb
280 lb	39 lb	44 lb
300 lb	42 lb	47 lb
320 lb	45 lb	50 lb

These targets assume:

• Full 6-month titration to maintenance dose
• Consistent medication adherence
• No major diet or exercise changes beyond what the medication naturally drives
• Average response (50% of patients will be above these numbers, 50% below)

Patients starting at 180 pounds should not expect 40-pound absolute losses at 6 months on standard doses. That would require 22% relative loss, which exceeds trial averages. Conversely, patients starting at 300 pounds should expect 40+ pound losses if they're achieving average relative loss.

The targets shift upward at 12 months. The STEP 5 trial showed peak loss at 16 to 18 months, with absolute losses roughly 1.3x the 6-month numbers. A patient losing 30 pounds at 6 months typically reaches 38 to 40 pounds by 12 months, then plateaus.

What happens when you compare yourself to trial averages

The most common source of patient frustration is comparing personal results to trial averages without accounting for starting weight differences.

A patient starting at 190 pounds on compounded semaglutide who loses 22 pounds in 6 months (11.6% relative loss) may feel disappointed because they "only" lost 22 pounds while the STEP 1 trial reported 33.7 pounds average. But the STEP 1 population had a mean baseline weight of 231 pounds. Adjusting for starting weight, the patient's 11.6% relative loss is only slightly below the trial's 14.9% average, representing a good response.

The inverse pattern: a patient starting at 280 pounds who loses 35 pounds (12.5% relative) may feel they're "not responding well" because they haven't hit 40+ pounds yet, when in fact their relative loss is on track with trial averages.

The solution is to convert your absolute loss to relative loss and compare percentages, not raw pounds. The formula is simple:

Relative loss (%) = (pounds lost / starting weight) × 100

If your relative loss at 6 months is:

• 12% to 16% on semaglutide 2.4 mg or tirzepatide 15 mg: you're in the average range
• 8% to 12% on semaglutide 1.7 mg or tirzepatide 10 mg: you're in the average range
• Above 16% on any dose: you're a strong responder
• Below 8% on maintenance dose after 6 months: discuss with your provider whether dose escalation or alternative approaches are warranted

The trial averages represent populations, not individuals. The STEP 1 standard deviation for relative loss was ±6.7%, meaning roughly one-third of patients fell outside the 8% to 21% range. Being below average doesn't mean treatment failure, and being above average doesn't guarantee long-term success. Both metrics are tools, not judgments.

FAQ

What is absolute weight loss? Absolute weight loss is the total amount of weight lost measured in pounds or kilograms, independent of starting weight. If you lose 30 pounds, that's your absolute loss regardless of whether you started at 200 or 300 pounds.

What is the difference between absolute and relative weight loss? Absolute loss is the raw number of pounds lost. Relative loss is the percentage of your starting body weight that you lost. A 30-pound loss from 200 pounds is 15% relative loss. The same 30 pounds from 300 pounds is 10% relative loss.

Which matters more for health, absolute or relative weight loss? Both matter for different outcomes. Absolute loss better predicts cardiovascular risk reduction, joint pain relief, and sleep apnea improvement. Relative loss better predicts diabetes remission, liver fat reduction, and insulin sensitivity improvements.

How much absolute weight loss can I expect on semaglutide? At 6 months on semaglutide 2.4 mg, expect 12% to 15% relative loss on average. For a 240-pound starting weight, that's 29 to 36 pounds absolute. For 180 pounds, it's 22 to 27 pounds. Absolute loss scales with starting weight.

How much absolute weight loss can I expect on tirzepatide? At 6 months on tirzepatide 15 mg, expect 14% to 16% relative loss on average. For a 240-pound starting weight, that's 34 to 38 pounds absolute. For 180 pounds, it's 25 to 29 pounds. Higher starting weights produce higher absolute losses.

Why do heavier people lose more absolute weight on GLP-1 medications? GLP-1 medications reduce caloric intake by a percentage (typically 20% to 30%), not a fixed amount. Heavier people have higher baseline caloric needs, so the same percentage reduction produces more absolute weight loss. Relative loss percentages are similar across starting weights.

Is 20 pounds of absolute weight loss enough to improve health? Yes. Studies show that 10 to 20 pounds of absolute loss reduces cardiovascular event risk by 10% to 15%, improves joint pain, and lowers sleep apnea severity. For metabolic outcomes like diabetes prevention, 7% to 10% relative loss (which could be 15 to 25 pounds depending on starting weight) is the threshold.

Should I set my weight loss goal in absolute pounds or percentage? Set goals based on your primary health outcome. If your main concern is joint pain or cardiovascular risk, use absolute pounds. If it's diabetes or metabolic health, use percentage. Most patients benefit from tracking both.

Why did I lose less absolute weight than the clinical trial average? First, convert your loss to a percentage and compare that to trial averages. You may have lost less absolute weight simply because you started at a lower weight. If your relative loss is also below average after 6+ months at maintenance dose, discuss dose adjustment with your provider.

Do clinical trials report absolute weight loss? Yes. Every major GLP-1 trial reports both absolute loss (in kilograms or pounds) and relative loss (percentage of body weight). Both appear in the primary outcome tables. Absolute loss is often reported as mean change from baseline.

Can I lose 50 pounds on a GLP-1 medication? It depends on your starting weight. A 50-pound absolute loss requires roughly 15% to 20% relative loss. If you start at 300+ pounds, 50 pounds is a realistic 6-to-12-month target. If you start at 200 pounds, 50 pounds would be 25% relative loss, which exceeds typical trial averages.

What is a realistic absolute weight loss goal for my starting weight? Multiply your starting weight by 0.12 to 0.16 for a 6-month target on tirzepatide 15 mg, or by 0.10 to 0.14 for semaglutide 2.4 mg. A 250-pound person should expect 30 to 40 pounds at 6 months. A 180-pound person should expect 22 to 29 pounds.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Wing RR et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Obesity. 2013.
4. Christensen R et al. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Arthritis Care & Research. 2018.
5. Lean MEJ et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2018.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
10. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
11. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
14. Lingvay I et al. Tirzepatide for the treatment of type 2 diabetes and obesity: a 2-year update. Diabetes, Obesity and Metabolism. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.